Based on the Burning Rock Biotech Ltd stock forecast from 0 analysts, the average analyst target price for Burning Rock Biotech Ltd is not available over the next 12 months. Burning Rock Biotech Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Burning Rock Biotech Ltd is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Burning Rock Biotech Ltd’s stock price was USD 0.83. Burning Rock Biotech Ltd’s stock price has changed by -7.78% over the past week, -17.00% over the past month and -66.93% over the last year.
No recent analyst target price found for Burning Rock Biotech Ltd
No recent average analyst rating found for Burning Rock Biotech Ltd
Company Overview Burning Rock Biotech Ltd
Bulletin Resources Limited operates as a minerals exploration company in Australia. The company primarily explores for gold, lithium, and nickel deposits. It holds interest in the Lake Rebecca gold project comprising various granted exploration license covering an area of 600 square kilometers located to the north-east of Kalgoorlie, Western Australia; Chifley gold project covering an area of 79 square kilometers; Ravensthorpe lithium project covering an area of 130 square kilometers; and Duketon North project located to the north-northwest of Laverton. The company was incorporated in 2010 and is headquartered in Perth, Australia. Address: 139 Newcastle Street, Perth, WA, Australia, 6000 Read Less
Bulletin Resources Limited operates as a minerals exploration company in Australia. The company primarily explores for gold, lithium, and nickel deposits. It holds interest in the Lake Rebecca gold project comprising various granted exploration license covering an area of 600 squ...Read More
Frequently Asked Questions About Burning Rock Biotech Ltd (BNR) Stock
Stock Target Advisor's fundamental analysis for Burning Rock Biotech Ltd's stock is Slightly Bearish.
Unfortunately we do not have enough data on BNR's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BNR's stock to indicate what its average analyst target is.
BNR stock's Price/Earning ratio is 92.11.
Our analysis grades BNR stock's Price / Earning ratio at F. This means that BNR stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Gold sector in the NSD exchange.
Based on this BNR may be a overvalued for its sector.
The last closing price of BNR's stock was USD 0.83.
The most recent market capitalization for BNR is USD 0.05B.
Unfortunately we do not have enough analyst data on BNR's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Burning Rock Biotech Ltd's stock.
As per our most recent records Burning Rock Biotech Ltd has 3 Employees.
Burning Rock Biotech Ltd's registered address is Messeallee 11, Essen, Germany, 45131.
You can get more information about it from Burning Rock Biotech Ltd's website at https://www.brenntag.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BNR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
